Genocea wraps up $30M round for T-cell vaccines

Genocea Biosciences has raised $30 million in a Series C financing round to advance its T-cell vaccines for infectious diseases. With the close of this financing round, the clinical-stage company has landed a total of $76 million in equity financing to date.

The Bill & Melinda Gates Foundation--well-known for providing grants to the vaccine industry--and CVF joined Genocea's existing partners, which include Polaris Venture Partners, Lux Capital, SR One, Johnson & Johnson Development Corp., Skyline Ventures, Cycad Group, Auriga Partners, MP Healthcare Ventures and Morningside.

Funds raised go toward advancing Genocea's two lead programs: GEN-003, a clinical-stage therapeutic vaccine candidate designed to reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe herpes simplex virus type 2, and GEN-004, a preclinical vaccine candidate to prevent Streptococcus pneumoniae infections. The company is in the Phase I/IIa study of GEN-003, expecting to report preliminary data in the second half of next year.

The Bill & Melinda Gates Foundation is no stranger to funding biotech research. In June, the foundation's head of global health, Trevor Mundel, indicated that the nonprofit planned to make investments in up to a dozen biotech companies this year. In late September, the foundation invested $6 million in Atreca to accelerate the discovery and development of novel vaccines and therapeutics for infectious diseases.

"We are excited about the potential of the partnership with Genocea to further our global health priorities," Mundel said in a statement. "T-cell innovation of this kind presents an intriguing opportunity to advance our global health mission through development of a new class of vaccines."

- see the release
- get more from FierceBiotech

Special Report: Genocea Biosciences - 2008 Fierce 15

Related Articles:
Atreca lands $6M for vaccine research
Gates Foundation readies a round of tempting biotech investments
Genocea's HSV-2 vax to hit the clinic
Genocea taps $35M venture round as it seeks new CEO

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.